Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The global liver fibrosis treatment market is expected to surpass an impressive valuation of US$ 16.43 billion in 2022 and is projected to exhibit a CAGR of 11% from 2022 to 2033. The primary factors of death and morbidity in individuals with liver cirrhosis are liver fibrosis and, in specific, cirrhosis. Their intervention or reversal has emerged as critical access points in clinical trials involving innovative liver-specific stimulants.
In persistent hepatitis B and C, significant advancements have been made with treatments that effectively address the consequence of fundamental liver damage. In the proportion of patients, extremely effective suppressive therapy can control strategies or even generate reversal, but this treatment remains elusive for the vast bulk of liver patients suffering from advanced alcoholic or nonalcoholic steatohepatitis, and genetic or immune deficiency liver failure.
Implementation for patients with liver fibrosis and personalized treatment is inextricably linked to the emergence of noninvasive fibrosis, fibrogenesis, and fibrosis biomarkers, which will continue to lead the industry. Cirrhosis is the 12th primary factor of death in the United States. Latest research has shown that liver fibrosis is a continual process and that initial cirrhosis may be recoverable. As a result, the treatment for liver fibrosis is expected to grow significantly over the next decades. Although liver biopsy is still the fundamental basis, transient elastography has become increasingly widely available and is quickly replacing biopsy as the preferred option for liver fibrosis staging which is contributing to the market expansion.
Furthermore, rising cancer cases, including liver cancer, are anticipated to propel the expansion of the global chronic liver disease therapeutic industry, contributing to market growth. For instance, the American Cancer Society estimates that 41,260 suspected cases of primary liver cancer were diagnosed in the United States in 2022 (28,600 in men and 12,660 in women).
Rising the number of various forms of chronic liver diseases is driving the market growth. For instance, Primary Sclerosing Cholangitis (PSC) is a chronic illness in which the bile ducts inside and outside the liver get to be sore and disfigured, ultimately narrowing and blocking, and causing liver damage. Based on the National Institute of Health, nonalcoholic fatty liver disease (NAFLD) represents the most prevalent liver disease, accounting for 25% of all cases worldwide. NAFLD and its variant, nonalcoholic steatohepatitis, influence 30% and 5% of the people in the United States, respectively. Therefore, treatment for liver fibrosis is expected to grow significantly in this country.
Hepatitis C therapeutics are becoming more widely used among healthcare professionals in the United States, and a growing number of patients are receiving them. This, integrated with a robust R&D pipeline and the introduction of novel medicines in the United States, is accelerating the expansion of the hepatitis C treatment marketplace in North America. For instance, in April 2019, the US Food and Drug Administration approved Mavyret by AbbVie as the first-ever treatment affirmed for pediatric Hepatitis C patients of all genotypes. As a result of these factors, the Liver Fibrosis Treatment Market is expected to grow in the coming decades.
The high incidence of Nonalcoholic steatohepatitis (NASH) also affects the population, fueling the market growth. NASH affects approximately 3% to 6% of the US inhabitants, and the pervasiveness is rising. Although there are several noninvasive screening and rating systems available to characterize NAFLD and NASH, liver biopsy is the only acceptable form for diagnosing NASH. Presently, the US Food and Drug Administration has not approved any NASH-specific therapies.
Data Points | Key Statistics |
---|---|
Expected Market Value (2022) | US$ 16.43 billion |
Anticipated Forecast Value (2033) | US$ 46.65 billion |
Projected Growth Rate (2022 to 2033) | 11% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The COVID-19 pandemic had an adverse effect on the global liver fibrosis therapeutics market, as the demand for medications used in liver rehabilitation decreased. Based on the National Center for Biotechnology Information, COVID-19 therapy in January 2020 involves discussing and parenterally administered agents, antivirals, immunomodulatory medicines, anti-cytokines, monoclonal antibodies, and miscellaneous agents. As a result, drugs demonstrated for use in other disease conditions have been produced in smaller quantities than those used in COVID-19 treatment. From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3%.
The rise in the prevalence of adverse outcomes such as patients with hepatitis B or C virus infection, a suppressed immune system owing to co-infection with human immunodeficiency virus (HIV), and the usage of immunosuppressive medicines after a liver transplant are poised to drive growth in the liver fibrosis treatment market over the forecast period. For instance, as per World Health Organization data released in 2022, 296 million individuals were estimated to be residing with chronic hepatitis B infection in 2019, with 1.5 million new infections each year. Hepatitis B caused an estimated 820 000 deaths in 2019, the majority of which were caused by cirrhosis and hepatocellular carcinoma.
Funding Approaches by multiple private research organizations to Drive Market
The increased research carried out by several private research organizations to develop treatments for liver fibrosis and other fatty liver diseases are anticipated to increase growth in the liver fibrosis treatment market. For instance, in August 2018, Virginia Tech's College of Science and the University of Virginia's Department of Pharmacology garnered US$400,000 in funding from the Virginia Biosciences Health Research Corporation (VBHRC), with Continuum Biosciences, Inc. matching funds. This grant, combined with matching funds, would assist scientists in creating drugs to treat nonalcoholic steatohepatitis (NASH).
Research and studies to evolve novel treatment therapies in liver fibrosis disease drive market growth
Expanding pre-clinical and clinical studies and development by prominent stakeholders to establish innovative treatment options in the liver fibrosis regime are predicted to propel the worldwide liver fibrosis treatment's future growth. For instance, the US Food and Drug Administration permitted Orphan Drug Designation to PTG-300, a subcutaneous injectable evolved by Protagonist Therapeutics, Inc., in March 2018. The PTG-300 is presently in a medical study for the treatment of beta-thalassemia and can also be employed to cure liver fibrosis.
High Costs to Hinder Market Growth
The massive cost necessary for drug assessment of the liver disease therapeutic process is one of the key factors impeding the expansion of the global liver fibrosis treatment market. According to the Centers for Disease Analysis, the United States invests $5 billion per year on disease-related healthcare costs like chemotherapy, transplants, screening, and hospitalizations.
The accessibility of a variety of Innovative Drug Molecules drive Asia Pacific market
Owing to the availability of a variety of novel drug molecules to improve the treatment process and technological development in rehabilitation in this region, North America leads the liver fibrosis market. Furthermore, surging medical spending and the emergence of major important players will speed up the market's pace of growth in this region. The mortality rate from liver diseases has increased, as has the occurrence of liver cancer.
Non-alcoholic fatty liver disorder (NAFLD) affects approximately 20% of Canadians, based on the Canadian Liver Foundation. Obesity is the primary factor of fatty liver disease in Canada. In 2018, nearly 30% of Canadians aged 18 and up reported being overweight or obese based on their height and weight.
Increasing Prevalence of Liver Fibrosis is Spurring Demand for Liver Fibrosis Treatment
Asia Pacific is predicted to expand during the forthcoming years owing to the rising incidence of liver fibrosis in this region. Moreover, the advancement of medical infrastructure and soaring regulatory reforms will enhance the industry's pace of growth in this region. During the projected period, the Asia Pacific market is projected to show the highest CAGR of 11.1%.
There is a growing patient pool of hepatitis C patients in developing nations like China, India, and other South-East Asian countries. Nevertheless, the patient population is dependent on the various governments for subsidized drugs, and earnings contribution is lesser; moreover, due to such aspects, the market in the Asia Pacific is growing rapidly.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Hospital Segment is Estimated to Hold the Largest Share
Based on end user, the global liver fibrosis treatment market is segmented into hospital, and Specialty Clinics. The hospital segment held the largest share of the market in 2021. Moreover, the same segment is expected to register the highest CAGR from 2022 to 2033.
Hepatotropic drug segment led the market in historical period
With a market share of 29.5% in 2021, the hepatotropic drug segment led the market. This increase is attributed to increased awareness of new drugs. Furthermore, hepatitis is a medical condition that primarily affects the liver, eventually contaminating the digestion process and the brain. HCV, HBV, and HAV are the three major types of hepatitis conditions. HCV is a major public health problem in which the liver becomes inflamed as a result of infection. As a result, this segment is expected to grow rapidly.
Key players in the Liver Fibrosis Treatment market are Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., Inventiva Pharma, Pharmaxis Limited.
Report Attribute | Details |
---|---|
Market Value in 2022 | US$ 2.5 billion |
Market Value in 2033 | US$ 46.65 billion |
Growth Rate | CAGR of 11% from 2022 to 2033 |
Base Year for Estimation | 2022 |
Historical Data | 2018 to 2022 |
Forecast Period | 2022 to 2033 |
Quantitative Units | Revenue in US$ Billion and CAGR from 2022 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization | Available Upon Request |
The market is estimated to reach US$ 46.65 billion by 2033.
Gilead Sciences, Inc., Merck & Co., Inc., and Bristol-Myers Squibb are key market players.
The market is forecasted to register a CAGR of 11% through 2033.
Asia Pacific is likely to expand at a CAGR of 11.1% through 2033.
The hospital sector held a significant share in 2021.
1. Executive Summary | Liver Fibrosis Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033 5.3.1. Peroxisome Proliferator-activated Receptors (PPAR)-alpha Agonist 5.3.2. ACE Inhibitors 5.3.3. Hepatotropic Drug 5.3.4. Others 5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Condition 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Condition, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Condition, 2023 to 2033 6.3.1. Chronic Liver Diseases 6.3.2. Hepatitis C 6.3.3. Nonalcoholic Steatohepatitis 6.4. Y-o-Y Growth Trend Analysis By Condition, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Condition, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User , 2023 to 2033 7.3.1. Hospitals 7.3.2. Specialty Clinics 7.3.3. Others 7.4. Y-o-Y Growth Trend Analysis By End User , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End User , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Treatment Type 9.2.3. By Condition 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment Type 9.3.3. By Condition 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Treatment Type 10.2.3. By Condition 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment Type 10.3.3. By Condition 10.3.4. By End User 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Treatment Type 11.2.3. By Condition 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment Type 11.3.3. By Condition 11.3.4. By End User 11.4. Key Takeaways 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.1.4. Singapore 12.2.1.5. Thailand 12.2.1.6. Indonesia 12.2.1.7. Australia 12.2.1.8. New Zealand 12.2.1.9. Rest of Asia Pacific 12.2.2. By Treatment Type 12.2.3. By Condition 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment Type 12.3.3. By Condition 12.3.4. By End User 12.4. Key Takeaways 13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Israel 13.2.1.4. Rest of MEA 13.2.2. By Treatment Type 13.2.3. By Condition 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment Type 13.3.3. By Condition 13.3.4. By End User 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. USA 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2022 14.1.2.1. By Treatment Type 14.1.2.2. By Condition 14.1.2.3. By End User 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2022 14.2.2.1. By Treatment Type 14.2.2.2. By Condition 14.2.2.3. By End User 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2022 14.3.2.1. By Treatment Type 14.3.2.2. By Condition 14.3.2.3. By End User 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2022 14.4.2.1. By Treatment Type 14.4.2.2. By Condition 14.4.2.3. By End User 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2022 14.5.2.1. By Treatment Type 14.5.2.2. By Condition 14.5.2.3. By End User 14.6. United Kingdom 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2022 14.6.2.1. By Treatment Type 14.6.2.2. By Condition 14.6.2.3. By End User 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2022 14.7.2.1. By Treatment Type 14.7.2.2. By Condition 14.7.2.3. By End User 14.8. Spain 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2022 14.8.2.1. By Treatment Type 14.8.2.2. By Condition 14.8.2.3. By End User 14.9. Italy 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2022 14.9.2.1. By Treatment Type 14.9.2.2. By Condition 14.9.2.3. By End User 14.10. China 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2022 14.10.2.1. By Treatment Type 14.10.2.2. By Condition 14.10.2.3. By End User 14.11. Japan 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2022 14.11.2.1. By Treatment Type 14.11.2.2. By Condition 14.11.2.3. By End User 14.12. South Korea 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2022 14.12.2.1. By Treatment Type 14.12.2.2. By Condition 14.12.2.3. By End User 14.13. Singapore 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2022 14.13.2.1. By Treatment Type 14.13.2.2. By Condition 14.13.2.3. By End User 14.14. Thailand 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2022 14.14.2.1. By Treatment Type 14.14.2.2. By Condition 14.14.2.3. By End User 14.15. Indonesia 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2022 14.15.2.1. By Treatment Type 14.15.2.2. By Condition 14.15.2.3. By End User 14.16. Australia 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2022 14.16.2.1. By Treatment Type 14.16.2.2. By Condition 14.16.2.3. By End User 14.17. New Zealand 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2022 14.17.2.1. By Treatment Type 14.17.2.2. By Condition 14.17.2.3. By End User 14.18. GCC Countries 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2022 14.18.2.1. By Treatment Type 14.18.2.2. By Condition 14.18.2.3. By End User 14.19. South Africa 14.19.1. Pricing Analysis 14.19.2. Market Share Analysis, 2022 14.19.2.1. By Treatment Type 14.19.2.2. By Condition 14.19.2.3. By End User 14.20. Israel 14.20.1. Pricing Analysis 14.20.2. Market Share Analysis, 2022 14.20.2.1. By Treatment Type 14.20.2.2. By Condition 14.20.2.3. By End User 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Treatment Type 15.3.3. By Condition 15.3.4. By End User 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Gilead Sciences, Inc. 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Merck & Co., Inc. 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. Bristol-Myers Squibb 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Johnson and Johnson 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Novartis AG 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Vertex Pharmaceuticals Incorporated 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Pfizer Inc. 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. FibroGen, Inc. 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. Inventiva Pharma 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. Pharmaxis Limited. 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Condition, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by End User , 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Condition, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by End User , 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 10: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Condition, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by End User , 2018 to 2033 Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 15: Europe Market Value (US$ Million) Forecast by Condition, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by End User , 2018 to 2033 Table 17: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 18: Asia Pacific Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 19: Asia Pacific Market Value (US$ Million) Forecast by Condition, 2018 to 2033 Table 20: Asia Pacific Market Value (US$ Million) Forecast by End User , 2018 to 2033 Table 21: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: MEA Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 23: MEA Market Value (US$ Million) Forecast by Condition, 2018 to 2033 Table 24: MEA Market Value (US$ Million) Forecast by End User , 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Condition, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by End User , 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by Condition, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by End User , 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by End User , 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033 Figure 17: Global Market Attractiveness by Treatment Type, 2023 to 2033 Figure 18: Global Market Attractiveness by Condition, 2023 to 2033 Figure 19: Global Market Attractiveness by End User , 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 22: North America Market Value (US$ Million) by Condition, 2023 to 2033 Figure 23: North America Market Value (US$ Million) by End User , 2023 to 2033 Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Condition, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by End User , 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by End User , 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033 Figure 37: North America Market Attractiveness by Treatment Type, 2023 to 2033 Figure 38: North America Market Attractiveness by Condition, 2023 to 2033 Figure 39: North America Market Attractiveness by End User , 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 42: Latin America Market Value (US$ Million) by Condition, 2023 to 2033 Figure 43: Latin America Market Value (US$ Million) by End User , 2023 to 2033 Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) Analysis by Condition, 2018 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) Analysis by End User , 2018 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User , 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033 Figure 57: Latin America Market Attractiveness by Treatment Type, 2023 to 2033 Figure 58: Latin America Market Attractiveness by Condition, 2023 to 2033 Figure 59: Latin America Market Attractiveness by End User , 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 62: Europe Market Value (US$ Million) by Condition, 2023 to 2033 Figure 63: Europe Market Value (US$ Million) by End User , 2023 to 2033 Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 69: Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 71: Europe Market Value (US$ Million) Analysis by Condition, 2018 to 2033 Figure 72: Europe Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033 Figure 74: Europe Market Value (US$ Million) Analysis by End User , 2018 to 2033 Figure 75: Europe Market Value Share (%) and BPS Analysis by End User , 2023 to 2033 Figure 76: Europe Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033 Figure 77: Europe Market Attractiveness by Treatment Type, 2023 to 2033 Figure 78: Europe Market Attractiveness by Condition, 2023 to 2033 Figure 79: Europe Market Attractiveness by End User , 2023 to 2033 Figure 80: Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: Asia Pacific Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 82: Asia Pacific Market Value (US$ Million) by Condition, 2023 to 2033 Figure 83: Asia Pacific Market Value (US$ Million) by End User , 2023 to 2033 Figure 84: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033 Figure 85: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: Asia Pacific Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 91: Asia Pacific Market Value (US$ Million) Analysis by Condition, 2018 to 2033 Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033 Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033 Figure 94: Asia Pacific Market Value (US$ Million) Analysis by End User , 2018 to 2033 Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by End User , 2023 to 2033 Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033 Figure 97: Asia Pacific Market Attractiveness by Treatment Type, 2023 to 2033 Figure 98: Asia Pacific Market Attractiveness by Condition, 2023 to 2033 Figure 99: Asia Pacific Market Attractiveness by End User , 2023 to 2033 Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033 Figure 101: MEA Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 102: MEA Market Value (US$ Million) by Condition, 2023 to 2033 Figure 103: MEA Market Value (US$ Million) by End User , 2023 to 2033 Figure 104: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 105: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: MEA Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 109: MEA Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 110: MEA Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 111: MEA Market Value (US$ Million) Analysis by Condition, 2018 to 2033 Figure 112: MEA Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033 Figure 113: MEA Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033 Figure 114: MEA Market Value (US$ Million) Analysis by End User , 2018 to 2033 Figure 115: MEA Market Value Share (%) and BPS Analysis by End User , 2023 to 2033 Figure 116: MEA Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033 Figure 117: MEA Market Attractiveness by Treatment Type, 2023 to 2033 Figure 118: MEA Market Attractiveness by Condition, 2023 to 2033 Figure 119: MEA Market Attractiveness by End User , 2023 to 2033 Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports